Uterine artery embolization in patients with autoimmune disease: A matched case-control study

Kichang Han, Man Deuk Kim, Wonseon Shin, Jason Jungsik Song, Joon Ho Kwon, Gyoung Min Kim, Jong Yun Won

Research output: Contribution to journalArticle

Abstract

OBJECTIVE. The purpose of this study is to investigate the safety of uterine artery embolization (UAE) for symptomatic leiomyomas in patients with autoimmune disease. MATERIALS AND METHODS. Of 1183 patients who underwent UAE for symptomatic leiomyomas, nine patients (mean age, 42.6 years; range, 34–49 years) with autoimmune disease were included in this study. An age- and disease-matched control group (n = 8) was randomly generated from our patient registry to compare the effectiveness and safety of UAE in patients with autoimmune disease. Volume reduction rates of the uterus and dominant leiomyoma and the change in C-reactive protein (CRP) levels before and after UAE were compared. RESULTS. Except for one patient who had Takayasu arteritis and indiscernible uterine arteries on angiogram, UAE was technically successful in both groups. All of the patients who underwent technically successful UAE experienced improvement or resolution of symptoms (16/16; 100%). Complete necrosis of dominant fibroids was achieved in all patients (16/16; 100%). Although there was no significant difference in the mean initial CRP level before UAE (0.4 ± 0.14 mg/L vs 1.06 ± 1.26 mg/L; p = 0.067), it was significantly higher in the autoimmune group 1 day after UAE (1.23 ± 0.6 mg/L vs 9.54 ± 6.63 mg/L; p = 0.001). There was no significant difference in the volume reduction rates of uterus and dominant leiomyoma. In the autoimmune group, there was one major adverse event that was not related to underlying disease. CONCLUSION. In patients with autoimmune disease, UAE could be considered for symptomatic leiomyomas, as long as the underlying disease is well controlled.

Original languageEnglish
Pages (from-to)1148-1153
Number of pages6
JournalAmerican Journal of Roentgenology
Volume212
Issue number5
DOIs
Publication statusPublished - 2019 May

Fingerprint

Uterine Artery Embolization
Autoimmune Diseases
Case-Control Studies
Leiomyoma
C-Reactive Protein
Uterus
Safety
Takayasu Arteritis
Uterine Artery
Registries
Angiography
Research Design
Necrosis

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

Han, Kichang ; Kim, Man Deuk ; Shin, Wonseon ; Song, Jason Jungsik ; Kwon, Joon Ho ; Kim, Gyoung Min ; Won, Jong Yun. / Uterine artery embolization in patients with autoimmune disease : A matched case-control study. In: American Journal of Roentgenology. 2019 ; Vol. 212, No. 5. pp. 1148-1153.
@article{a51a8b67d3b940f3a097a37f1212a6b3,
title = "Uterine artery embolization in patients with autoimmune disease: A matched case-control study",
abstract = "OBJECTIVE. The purpose of this study is to investigate the safety of uterine artery embolization (UAE) for symptomatic leiomyomas in patients with autoimmune disease. MATERIALS AND METHODS. Of 1183 patients who underwent UAE for symptomatic leiomyomas, nine patients (mean age, 42.6 years; range, 34–49 years) with autoimmune disease were included in this study. An age- and disease-matched control group (n = 8) was randomly generated from our patient registry to compare the effectiveness and safety of UAE in patients with autoimmune disease. Volume reduction rates of the uterus and dominant leiomyoma and the change in C-reactive protein (CRP) levels before and after UAE were compared. RESULTS. Except for one patient who had Takayasu arteritis and indiscernible uterine arteries on angiogram, UAE was technically successful in both groups. All of the patients who underwent technically successful UAE experienced improvement or resolution of symptoms (16/16; 100{\%}). Complete necrosis of dominant fibroids was achieved in all patients (16/16; 100{\%}). Although there was no significant difference in the mean initial CRP level before UAE (0.4 ± 0.14 mg/L vs 1.06 ± 1.26 mg/L; p = 0.067), it was significantly higher in the autoimmune group 1 day after UAE (1.23 ± 0.6 mg/L vs 9.54 ± 6.63 mg/L; p = 0.001). There was no significant difference in the volume reduction rates of uterus and dominant leiomyoma. In the autoimmune group, there was one major adverse event that was not related to underlying disease. CONCLUSION. In patients with autoimmune disease, UAE could be considered for symptomatic leiomyomas, as long as the underlying disease is well controlled.",
author = "Kichang Han and Kim, {Man Deuk} and Wonseon Shin and Song, {Jason Jungsik} and Kwon, {Joon Ho} and Kim, {Gyoung Min} and Won, {Jong Yun}",
year = "2019",
month = "5",
doi = "10.2214/AJR.18.20432",
language = "English",
volume = "212",
pages = "1148--1153",
journal = "American Journal of Roentgenology",
issn = "0361-803X",
publisher = "American Roentgen Ray Society",
number = "5",

}

Uterine artery embolization in patients with autoimmune disease : A matched case-control study. / Han, Kichang; Kim, Man Deuk; Shin, Wonseon; Song, Jason Jungsik; Kwon, Joon Ho; Kim, Gyoung Min; Won, Jong Yun.

In: American Journal of Roentgenology, Vol. 212, No. 5, 05.2019, p. 1148-1153.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Uterine artery embolization in patients with autoimmune disease

T2 - A matched case-control study

AU - Han, Kichang

AU - Kim, Man Deuk

AU - Shin, Wonseon

AU - Song, Jason Jungsik

AU - Kwon, Joon Ho

AU - Kim, Gyoung Min

AU - Won, Jong Yun

PY - 2019/5

Y1 - 2019/5

N2 - OBJECTIVE. The purpose of this study is to investigate the safety of uterine artery embolization (UAE) for symptomatic leiomyomas in patients with autoimmune disease. MATERIALS AND METHODS. Of 1183 patients who underwent UAE for symptomatic leiomyomas, nine patients (mean age, 42.6 years; range, 34–49 years) with autoimmune disease were included in this study. An age- and disease-matched control group (n = 8) was randomly generated from our patient registry to compare the effectiveness and safety of UAE in patients with autoimmune disease. Volume reduction rates of the uterus and dominant leiomyoma and the change in C-reactive protein (CRP) levels before and after UAE were compared. RESULTS. Except for one patient who had Takayasu arteritis and indiscernible uterine arteries on angiogram, UAE was technically successful in both groups. All of the patients who underwent technically successful UAE experienced improvement or resolution of symptoms (16/16; 100%). Complete necrosis of dominant fibroids was achieved in all patients (16/16; 100%). Although there was no significant difference in the mean initial CRP level before UAE (0.4 ± 0.14 mg/L vs 1.06 ± 1.26 mg/L; p = 0.067), it was significantly higher in the autoimmune group 1 day after UAE (1.23 ± 0.6 mg/L vs 9.54 ± 6.63 mg/L; p = 0.001). There was no significant difference in the volume reduction rates of uterus and dominant leiomyoma. In the autoimmune group, there was one major adverse event that was not related to underlying disease. CONCLUSION. In patients with autoimmune disease, UAE could be considered for symptomatic leiomyomas, as long as the underlying disease is well controlled.

AB - OBJECTIVE. The purpose of this study is to investigate the safety of uterine artery embolization (UAE) for symptomatic leiomyomas in patients with autoimmune disease. MATERIALS AND METHODS. Of 1183 patients who underwent UAE for symptomatic leiomyomas, nine patients (mean age, 42.6 years; range, 34–49 years) with autoimmune disease were included in this study. An age- and disease-matched control group (n = 8) was randomly generated from our patient registry to compare the effectiveness and safety of UAE in patients with autoimmune disease. Volume reduction rates of the uterus and dominant leiomyoma and the change in C-reactive protein (CRP) levels before and after UAE were compared. RESULTS. Except for one patient who had Takayasu arteritis and indiscernible uterine arteries on angiogram, UAE was technically successful in both groups. All of the patients who underwent technically successful UAE experienced improvement or resolution of symptoms (16/16; 100%). Complete necrosis of dominant fibroids was achieved in all patients (16/16; 100%). Although there was no significant difference in the mean initial CRP level before UAE (0.4 ± 0.14 mg/L vs 1.06 ± 1.26 mg/L; p = 0.067), it was significantly higher in the autoimmune group 1 day after UAE (1.23 ± 0.6 mg/L vs 9.54 ± 6.63 mg/L; p = 0.001). There was no significant difference in the volume reduction rates of uterus and dominant leiomyoma. In the autoimmune group, there was one major adverse event that was not related to underlying disease. CONCLUSION. In patients with autoimmune disease, UAE could be considered for symptomatic leiomyomas, as long as the underlying disease is well controlled.

UR - http://www.scopus.com/inward/record.url?scp=85065664090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065664090&partnerID=8YFLogxK

U2 - 10.2214/AJR.18.20432

DO - 10.2214/AJR.18.20432

M3 - Article

AN - SCOPUS:85065664090

VL - 212

SP - 1148

EP - 1153

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

SN - 0361-803X

IS - 5

ER -